Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy.As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to identify patients who might respond to EGFR-targeted